{"article_title": "NeuroPhage adds $10M to its Series D to bring brain plaque-clearing Alzheimer's drug to clinic", "article_keywords": ["agingrelated", "adds", "d", "plaqueclearing", "series", "million", "parkinsons", "disease", "drug", "bring", "clinic", "brain", "alzheimers", "way", "technology", "works", "neurophage", "solomon"], "article_url": "http://medcitynews.com/2015/01/neurophage/", "article_text": "Cambridge-based NeuroPhage is developing, well, a better way to clear the trash. It\u2019s chasing Alzheimer\u2019s, Parkinson\u2019s and other aging-related degenerative diseases with a technology that breaks up disease-causing plaques in the brain.\n\nThe company just tacked on another $10 million to its existing Series D private equity financing, bringing that total round to $27 million. To date, NeuroPhage has raised some $61.5 million, with the dollars coming largely from \u201cvery high net individuals.\u201d\n\nThe money\u2019s slated to advance NPT088, NeuroPhage\u2019s lead candidate, into clinical studies for Alzheimer\u2019s by the end of this year. The company plans to enroll 50 patients into the phase 1 trial that shows not proof of concept, but proof of activity. While the candidate\u2019s performed well preclinically, this will be the real test of the NeuroPhage platform.\n\nCEO Jonathon Solomon had a garbage analogy to explain the biochemistry of aging-related disease: The body\u2019s a manufacturing plant of proteins \u2013 necessary but sticky things that aggregate if they aren\u2019t cleared up. Protein misfolding leads to the longterm aggregation of these plaques \u2013 causing diseases like Alzheimer\u2019s, Parkinson\u2019s and others.\n\n\u201cAs we age, our garbage removal system becomes less efficacious,\u201d Solomon said.\n\nIts GAIM \u2013 general amyloid interaction motif \u2013 can simultaneously target a wide array of misfolded proteins associated with aging-related disease. The phage-based treatment works much as a virus invades a cell \u2013 changing the structure of the misfolded protein with a hijacking.\n\nThe work\u2019s been quite effective in animal models \u2013 mice treated with the GAIM technology have seen a dramatic reduction in pathology, cognitive improvement and restoration of memory loss. This isn\u2019t a silver bullet \u2013 Solomon says there\u2019s no way to recover memories lost from cells that have already died, but the intervention could help restore brain plasticity and potentially help rehabilitate someone with a serious degenerative disorder.\n\n\u201cIf it works \u2013 and we prove this mechanism works \u2013 we\u2019ll explore this with many other indications. Like Parkinson\u2019s disease, and some orphan indications,\u201d Solomon said.\n\nRecent data from Biogen Idec \u2013 showing improvements in patients once beta amyloid has reduced in the brain \u2013 has bolstered NeuroPhage\u2019s confidence in its own product, Solomon said.", "article_metadata": {"description": "Cambridge-based\u00a0NeuroPhage\u00a0is developing, well, a better\u00a0way to clear the trash.\u00a0It\u2019s chasing Alzheimer\u2019s, Parkinson\u2019s and other aging-related degenerative diseases with a technology that breaks up disease-causing plaques in the brain. The company just tacked on another $10 million to its existing Series D private equity financing, bringing that total round to $27 million. To date, NeuroPhage has raised some $61.5 million, with the dollars coming largely from \u201cvery high net individuals.\u201d The money\u2019s slated to advance NPT088, NeuroPhage\u2019s lead candidate, into clinical studies for Alzheimer\u2019s by the end of this year. The company plans to enroll 50 patients into the phase 1 trial that shows not proof of concept, but proof of activity.\u00a0While the candidate\u2019s\u00a0performed well preclinically, this will be the real test of the NeuroPhage platform. CEO Jonathon\u00a0Solomon had a garbage\u00a0analogy to explain\u00a0the biochemistry of aging-related disease: The body\u2019s a\u00a0manufacturing plant of proteins \u2013 necessary but sticky things that aggregate if they aren\u2019t cleared up.\u00a0Protein misfolding\u00a0leads to the longterm aggregation of these plaques\u00a0\u2013 causing\u00a0diseases like Alzheimer\u2019s, Parkinson\u2019s and others. \u201cAs we age, our garbage removal system becomes less efficacious,\u201d Solomon said. Its\u00a0GAIM \u2013 general amyloid interaction motif \u2013 can simultaneously target a wide array of misfolded proteins associated with aging-related disease. The phage-based treatment works much as a virus invades a cell \u2013 changing the structure of the misfolded protein with a hijacking. The work\u2019s been quite effective in animal models \u2013 mice treated with the GAIM technology have seen a dramatic reduction in pathology, cognitive improvement and restoration of memory loss. This isn\u2019t a silver bullet \u2013 Solomon says there\u2019s no way to recover memories lost from cells that have already died, but the intervention could help restore brain plasticity and potentially help rehabilitate someone with a serious degenerative disorder. \u201cIf it works \u2013 and we prove this mechanism works \u2013 we\u2019ll explore this with many other indications. Like\u00a0Parkinson\u2019s disease, and some orphan indications,\u201d Solomon said. Recent data from Biogen Idec \u2013 showing improvements in patients once beta amyloid has reduced in the brain \u2013 has bolstered NeuroPhage\u2019s confidence in its own product, Solomon said.", "generator": "WordPress 4.5.2", "og": {"site_name": "MedCity News", "description": "Cambridge-based\u00a0NeuroPhage\u00a0is developing, well, a better\u00a0way to clear the trash.\u00a0It\u2019s chasing Alzheimer\u2019s, Parkinson\u2019s and other aging-related degenerative diseases with a technology that breaks up disease-causing plaques in the brain. The company just tacked on another $10 million to its existing Series D private equity financing, bringing that total round to $27 million. To date, NeuroPhage has raised some $61.5 million, with the dollars coming largely from \u201cvery high net individuals.\u201d The money\u2019s slated to advance NPT088, NeuroPhage\u2019s lead candidate, into clinical studies for Alzheimer\u2019s by the end of this year. The company plans to enroll 50 patients into the phase 1 trial that shows not proof of concept, but proof of activity.\u00a0While the candidate\u2019s\u00a0performed well preclinically, this will be the real test of the NeuroPhage platform. CEO Jonathon\u00a0Solomon had a garbage\u00a0analogy to explain\u00a0the biochemistry of aging-related disease: The body\u2019s a\u00a0manufacturing plant of proteins \u2013 necessary but sticky things that aggregate if they aren\u2019t cleared up.\u00a0Protein misfolding\u00a0leads to the longterm aggregation of these plaques\u00a0\u2013 causing\u00a0diseases like Alzheimer\u2019s, Parkinson\u2019s and others. \u201cAs we age, our garbage removal system becomes less efficacious,\u201d Solomon said. Its\u00a0GAIM \u2013 general amyloid interaction motif \u2013 can simultaneously target a wide array of misfolded proteins associated with aging-related disease. The phage-based treatment works much as a virus invades a cell \u2013 changing the structure of the misfolded protein with a hijacking. The work\u2019s been quite effective in animal models \u2013 mice treated with the GAIM technology have seen a dramatic reduction in pathology, cognitive improvement and restoration of memory loss. This isn\u2019t a silver bullet \u2013 Solomon says there\u2019s no way to recover memories lost from cells that have already died, but the intervention could help restore brain plasticity and potentially help rehabilitate someone with a serious degenerative disorder. \u201cIf it works \u2013 and we prove this mechanism works \u2013 we\u2019ll explore this with many other indications. Like\u00a0Parkinson\u2019s disease, and some orphan indications,\u201d Solomon said. Recent data from Biogen Idec \u2013 showing improvements in patients once beta amyloid has reduced in the brain \u2013 has bolstered NeuroPhage\u2019s confidence in its own product, Solomon said.", "title": "NeuroPhage adds $10M to its Series D to bring brain plaque-clearing Alzheimer\u2019s drug to clinic", "locale": "en_US", "image": "http://medcitynews.com/wp-content/uploads/model-of-the-brain1.jpg", "updated_time": "2015-01-17T01:19:13-04:00", "url": "http://medcitynews.com/2015/01/neurophage/", "type": "article"}, "twitter": {"image": "http://medcitynews.com/wp-content/uploads/model-of-the-brain1.jpg", "title": "NeuroPhage adds $10M to its Series D to bring brain plaque-clearing Alzheimer's drug to clinic - MedCity News", "description": "Cambridge-based\u00a0NeuroPhage\u00a0is developing, well, a better\u00a0way to clear the trash.\u00a0It\u2019s chasing Alzheimer\u2019s, Parkinson\u2019s and other aging-related degenerative diseases with a technology that breaks up disease-causing plaques in the brain. The company just tacked on another $10 million to its existing Series D private equity financing, bringing that total round to $27 million. To date, NeuroPhage has raised some $61.5 million, with the dollars coming largely from \u201cvery high net individuals.\u201d The money\u2019s slated to advance NPT088, NeuroPhage\u2019s lead candidate, into clinical studies for Alzheimer\u2019s by the end of this year. The company plans to enroll 50 patients into the phase 1 trial that shows not proof of concept, but proof of activity.\u00a0While the candidate\u2019s\u00a0performed well preclinically, this will be the real test of the NeuroPhage platform. CEO Jonathon\u00a0Solomon had a garbage\u00a0analogy to explain\u00a0the biochemistry of aging-related disease: The body\u2019s a\u00a0manufacturing plant of proteins \u2013 necessary but sticky things that aggregate if they aren\u2019t cleared up.\u00a0Protein misfolding\u00a0leads to the longterm aggregation of these plaques\u00a0\u2013 causing\u00a0diseases like Alzheimer\u2019s, Parkinson\u2019s and others. \u201cAs we age, our garbage removal system becomes less efficacious,\u201d Solomon said. Its\u00a0GAIM \u2013 general amyloid interaction motif \u2013 can simultaneously target a wide array of misfolded proteins associated with aging-related disease. The phage-based treatment works much as a virus invades a cell \u2013 changing the structure of the misfolded protein with a hijacking. The work\u2019s been quite effective in animal models \u2013 mice treated with the GAIM technology have seen a dramatic reduction in pathology, cognitive improvement and restoration of memory loss. This isn\u2019t a silver bullet \u2013 Solomon says there\u2019s no way to recover memories lost from cells that have already died, but the intervention could help restore brain plasticity and potentially help rehabilitate someone with a serious degenerative disorder. \u201cIf it works \u2013 and we prove this mechanism works \u2013 we\u2019ll explore this with many other indications. Like\u00a0Parkinson\u2019s disease, and some orphan indications,\u201d Solomon said. Recent data from Biogen Idec \u2013 showing improvements in patients once beta amyloid has reduced in the brain \u2013 has bolstered NeuroPhage\u2019s confidence in its own product, Solomon said.", "card": "summary", "creator": "@meghanakeshavan"}, "robots": "noodp", "fb": {"app_id": 148725768475669}, "article": {"section": "Daily", "tag": "neurophage", "published_time": "2015-01-16T05:30:44-04:00", "modified_time": "2015-01-17T01:19:13-04:00"}, "keywords": "weight loss, obesity, overweight,diabetes,massachusetts,medical devices,obesity,startups,healthcare innovation, medcity news,medcity news,san francisco, startups, life sciences,accelerator,rock health,startup advice,startup funding,patient monitoring system, motion sensors ,dc,healthcare it,washington,foodborne pathogens, diagnostics company, diagnostic platforms,minimally invasive surgery, laser surgery,cambridge,dealflow,hospitals,wellpoint, healthways, health and wellness, employee wellness programs,investing,wellness,medtronic, shanghai innovation center, china, r&d,china,mdt,minneapolis,minnesota,publics,twin cities,ulcerative colitis, abbott labs, humira,abbott labs,doctors,pharmaceuticals,skin disorders, pharmaceuticals, md anderson cancer center,cancer,texas,renal denervation, st. jude medical,st. jude medical,stj,emr, ehr, electronic health records, electronic medical records, certified emr,certified emr,ehr,electronic health records,electronic medical records,advanced cellular technology,amyotrophic lateral sclerosis,embryonic stem cells,geron corporation,lou gehrig\\'s disease,macular degeneration,regenerative medicine,spinal cord damage,value-based healthcare system, obamacare, fee-for-service model,california,cleveland,health insurance,insurance,ohio,pennsylvania,politics,cancer treatment options library, aetna, aet, healthcare it,aet,aetna,health it,phi,philadelphia,alzheimer's disease, neurodegenerative disease, neurophage, , MedCity News", "google-site-verification": "xudQg7nxVR9ifmMTY4Tf-0wVtX9b6rWLQd0utCweGOc", "viewport": "width=device-width,initial-scale=1.0,width=device-width,user-scalable=no,minimum-scale=1.0,maximum-scale=1.0"}, "_id": "\"57477af46914bd0286fde32c\"", "article_summary": "It\u2019s chasing Alzheimer\u2019s, Parkinson\u2019s and other aging-related degenerative diseases with a technology that breaks up disease-causing plaques in the brain.\nProtein misfolding leads to the longterm aggregation of these plaques \u2013 causing diseases like Alzheimer\u2019s, Parkinson\u2019s and others.\nIts GAIM \u2013 general amyloid interaction motif \u2013 can simultaneously target a wide array of misfolded proteins associated with aging-related disease.\nLike Parkinson\u2019s disease, and some orphan indications,\u201d Solomon said.\nThe company just tacked on another $10 million to its existing Series D private equity financing, bringing that total round to $27 million."}